FindTrial
Sign In

Recombinant Factor VII for Intractable Postpartum Haemorrhage

Recombinant Factor VII for the Conservative Management Trials of Intractable Postpartum Haemorrhage: is it a Drug Effect , Operator Experience or Inherent Result of the Aetiology.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05298826
Enrollment
41
Registered
2022-03-28
Start date
2019-06-01
Completion date
2020-01-10
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Partum Hemorrhage

Brief summary

Postpartum haemorrhage remains at the top of the causes of maternal deaths in both developed and developing countries .

Detailed description

Major postpartum haemorrhage is a dangerous complication that accounts for the highest maternal morbidity rate

Interventions

DRUGrecombinant factor VIIa

using recombinant factor VIIa

Sponsors

Aljazeera Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Women with severe resistant postpartum hemorage

Exclusion criteria

* women without postpartum hemorage

Design outcomes

Primary

MeasureTime frameDescription
The number of women who had hysterectomy24 hoursnumber of women resistant to the treatment and needed hysterectomy

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026